Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05379985 |
Recruitment Status :
Recruiting
First Posted : May 18, 2022
Last Update Posted : February 23, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-small Cell Lung Cancer (NSCLC) Colorectal Cancer (CRC) Pancreatic Ductal Adenocarcinoma (PDAC) Advanced Solid Tumors | Drug: RMC-6236 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 474 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multicenter Open-Label Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS |
Actual Study Start Date : | May 31, 2022 |
Estimated Primary Completion Date : | June 2024 |
Estimated Study Completion Date : | December 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Experimental: RMC-6236
Enrollment into dose exploration may be from any advanced solid tumor type with KRAS p.G12 mutations. Enrollment into dose expansion/optimization may be from groups consisting of patients with a single histotype/genotype (for example, KRAS G12-mutated NSCLC, PDAC, CRC, RAS mutant NSCLC, PDAC, CRC, Melanoma, gynecological cancer or other solid tumors not previously specified). RAS mutant is defined as any nonsynonymous mutation of KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61) |
Drug: RMC-6236
Oral Tablets |
- Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs [ Time Frame: up to 2.5 years ]
- Number of Participants with Dose-Limiting Toxicity (DLT) [ Time Frame: 21 days ]
- Maximum Observed Blood Concentration (Cmax) of RMC-6236 [ Time Frame: up to 15 weeks ]
- Time to Reach Maximum Blood Concentration (Tmax) of RMC-6236 [ Time Frame: up to 15 weeks ]
- Area Under Blood Concentration Time Curve (AUC) of RMC-6236 [ Time Frame: up to 15 weeks ]
- Elimination Half-Life of RMC-6236 (t1/2) [ Time Frame: up to 15 weeks ]
- Ratio of accumulation of RMC-6236 from a single dose to steady state with repeated dosing [ Time Frame: up to 15 weeks ]
- Overall Response Rate (ORR) [ Time Frame: up to 2.5 years ]Overall response rate per RECIST v1.1
- Duration of Response (DOR) [ Time Frame: up to 2.5 years ]Duration of response per RECIST v1.1
- Disease Control Rate (DCR) [ Time Frame: up to 2.5 years ]Disease control rate per RECIST v1.1
- Time to Response (TTR) [ Time Frame: up to 2.5 years ]Time to response per RECIST v1.1
- Progression-Free Survival (PFS) [ Time Frame: up to 2.5 years ]Progression-free survival per RECIST v1.1
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing.
- Received prior standard therapy appropriate for tumor type and stage
- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate organ function
Exclusion Criteria:
- Primary central nervous system (CNS) tumors
- Active, untreated brain metastases
- Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
- History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
Other inclusion/exclusion criteria may apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05379985
Contact: Revolution Medicines, Inc. | (650) 779-2300 | rmc-6236_ct-inquiry@revmed.com |
United States, California | |
UC Irvine/Chao Family Comprehensive Cancer Center | Recruiting |
Orange, California, United States, 92868 | |
UCLA | Recruiting |
Santa Monica, California, United States, 90404 | |
United States, Maryland | |
Johns Hopkins University | Recruiting |
Baltimore, Maryland, United States, 21287 | |
United States, Massachusetts | |
Dana Farber Cancer Institute | Recruiting |
Boston, Massachusetts, United States, 02215 | |
United States, New York | |
Perlmutter Cancer Center at NYU Langone Health | Recruiting |
New York, New York, United States, 10016 | |
Memorial Sloan-Kettering Cancer Center | Recruiting |
New York, New York, United States, 10021 | |
Columbia University | Recruiting |
New York, New York, United States, 10032 | |
United States, Ohio | |
Christ Hospital Cancer Center | Recruiting |
Cincinnati, Ohio, United States, 45219 | |
United States, Tennessee | |
Sarah Cannon Research Institute | Recruiting |
Nashville, Tennessee, United States, 37203 | |
United States, Texas | |
University of Texas at Austin | Recruiting |
Austin, Texas, United States, 78712 | |
Mary Crowley Cancer Research | Recruiting |
Dallas, Texas, United States, 75230 | |
The University of Texas MD Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Next Oncology | Recruiting |
San Antonio, Texas, United States, 78229 | |
United States, Utah | |
Huntsman Cancer Institute | Recruiting |
Salt Lake City, Utah, United States, 84112 | |
United States, Virginia | |
Next Oncology Virginia | Recruiting |
Fairfax, Virginia, United States, 22031 |
Study Director: | Revolution Medicines, Inc. | Revolution Medicines, Inc. |
Responsible Party: | Revolution Medicines, Inc. |
ClinicalTrials.gov Identifier: | NCT05379985 |
Other Study ID Numbers: |
RMC-6236-001 |
First Posted: | May 18, 2022 Key Record Dates |
Last Update Posted: | February 23, 2024 |
Last Verified: | February 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
KRAS Non-small Cell Lung Cancer Lung Cancer Colorectal Cancer Colon Cancer Metastatic Cancer Pancreatic Cancer Pancreatic Ductal Adenocarcinoma NSCLC CRC PDAC Pancreatic Neoplasms Carcinoma, Pancreatic Ductal |
Colorectal Neoplasms Colonic Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Lung Neoplasms Carcinoma, Non-Small-Cell Lung Neoplastic Processes Thoracic Neoplasms Antineoplastic Agents Melanoma Gynecological Cancers RAS |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Adenocarcinoma Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |
Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |